The CAR T-cell therapies market has witnessed significant advancements in recent years, with specific segments driving growth due to increased incidences of cancer and innovations in treatment options. Among these, the axicabtagene ciloleucel segment is holding a dominant position, while the tisagenlecleucel segment is expected to see substantial growth in the coming years. The lymphoma segment led the market in 2024, while acute lymphocytic leukemia is anticipated to grow rapidly. The hospitals segment remains the largest market player, but the cancer treatment centers segment is projected to expand at the fastest pace.
The global CAR T-cell therapies market is estimated to grow from USD 6.52 billion in 2024, at a compound annual growth rate (CAGR) of 29.8%, reaching an estimated USD 88.51 billion by 2034. This growth is attributed to several factors, including extensive clinical trials, a rising prevalence of cancer, and favorable government policies that are accelerating the adoption of CAR T-cell therapies worldwide.
Get All the Details on Our Solutions – Brochure Download @ https://www.towardshealthcare.com/download-brochure/5028
Axicabtagene Ciloleucel Segment: Dominating the Market
Axicabtagene ciloleucel, also known as Yescarta, is a leader in the CAR T-cell therapies market. In 2024, this drug type held a dominant position due to its use as a second-line treatment for large B-cell lymphoma that has failed conventional therapies. The rise in the number of B-cell lymphoma cases has significantly contributed to the segment’s growth. As an advanced treatment, axicabtagene ciloleucel offers a targeted approach to treating lymphoma, positioning it as a top choice in the CAR T-cell therapy landscape.
Tisagenlecleucel Segment: Significantly Growing
Tisagenlecleucel, known as Kymriah, is gaining traction in the CAR T-cell therapies market, especially for its use in treating certain types of B-cell non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia (ALL). Predicted to experience significant growth, tisagenlecleucel stands out due to its favorable safety profile, particularly in young children and infants. This makes it a popular choice for treating pediatric patients, which further drives its demand. Additionally, greater survival rates for patients treated with tisagenlecleucel add to its attractiveness, ensuring its continued growth in the market.
Lymphoma Segment: Leading in 2024
By indication, the lymphoma segment led the global CAR T-cell therapies market in 2024. Lymphoma, a cancer that affects the lymphatic system, is becoming more prevalent, which has fueled the demand for innovative treatments such as CAR T-cell therapies. The increasing incidence of lymphoma, coupled with growing research and development activities, underscores the need for such therapies. With a lack of viable small-molecule treatments for lymphoma, CAR T-cell therapies are emerging as a groundbreaking option for patients battling this disease.
Acute Lymphocytic Leukemia Segment: Fastest-Growing
While lymphoma remains the leading indication for CAR T-cell therapies, the acute lymphocytic leukemia (ALL) segment is poised for rapid growth. ALL is a cancer that affects the blood and bone marrow, and its increasing prevalence is expected to drive the demand for CAR T-cell therapies. The severity of ALL and its resistance to conventional treatments have propelled the search for more effective therapies, contributing to the segment’s projected growth.
Hospitals Segment: Holding the Largest Share
By end-user, hospitals dominate the CAR T-cell therapies market, holding the largest share in 2024. Hospitals offer the infrastructure, specialized equipment, and skilled medical personnel necessary to administer CAR T-cell therapies. Additionally, favorable reimbursement policies and substantial capital investments have made hospitals the primary point of care for CAR T-cell treatments. As the adoption of CAR T-cell therapies increases, especially in both developed and developing countries, hospitals remain the primary hub for these treatments.
Cancer Treatment Centers Segment: Fastest-Growing
Although hospitals hold the largest share, cancer treatment centers are expected to experience the highest growth in the CAR T-cell therapies market. These centers are equipped with specialized instruments and have the expertise required to provide CAR T-cell therapies. As cancer incidences continue to rise, so too does the demand for advanced treatment options. The expansion of cancer treatment centers globally, driven by this demand, will further contribute to the market’s overall growth, positioning cancer treatment centers as the fastest-growing segment.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/car-t-cell-therapies-are-poised-for-the-next-wave-of-innovation
Invest in Our Premium Strategic Solution @ https://www.towardshealthcare.com/price/5028
We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com
Web: https://www.towardshealthcare.com
Visit Dental Specifics: https://www.towardsdental.com
Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
